Parabilis Medicines, the decade-old and well-funded
Parabilis Medicines, the decade-old and well-funded “undruggable” biotech out of Greg Verdine’s Harvard lab, seeks to become the 12th drug developer to conduct an initial …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets
Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates
Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
Høeg fired in latest FDA shakeup; 20 people die after taking Amgen drug
A new ranking of pharma companies by R&D performance
Amplia takes aim at billion-dollar pancreatic cancer drug market
Inside Incyte’s $120 Million AI For Drug Development Deal
Drugmakers guard IP more tightly amid China competition
